Dr. Borys Hrinczenko

Hematology
2900 Collins Rd, 
Lansing, MI 
2900 Collins Rd, 
Lansing, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Borys Hrinczenko is a Hematologist in Lansing, Michigan. Dr. Hrinczenko is rated as an Experienced provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Multiple Myeloma, Sickle Cell Disease, ALK-Positive Non-Small Cell Lung Cancer, and Thrombocytopenia.

His clinical research consists of co-authoring 19 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in OH
Hospital Affiliations
Edward W Sparrow Hospital
Mclaren Greater Lansing
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

MCLAREN GREATER LANSING
2900 Collins Rd, Lansing, MI 48910
Other Locations
MCLAREN GREATER LANSING
1540 Lake Lansing Rd, Lansing, MI 48912

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: July 17, 2025
Intervention Type: Other, Drug
Study Drug: Naloxegol
Study Phase: Phase 2
Phase II Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081
Phase II Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081
Enrollment Status: Completed
Publish Date: March 11, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012
A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012
Enrollment Status: Completed
Publish Date: September 25, 2023
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 2
View 4 Less Clinical Trials

19 Total Publications

A Trend Analysis of Metastatic Lung Cancer Disparities in the United States in the Era of Lung Cancer Screening.
A Trend Analysis of Metastatic Lung Cancer Disparities in the United States in the Era of Lung Cancer Screening.
Journal: Cureus
Published: May 31, 2025
Similar Doctors
Distinguished in Inflammatory Breast Cancer
Dr. Catherine H. Van Poznak
Oncology | Hematology
Distinguished in Inflammatory Breast Cancer
Dr. Catherine H. Van Poznak
Oncology | Hematology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr, 
Ann Arbor, MI 
 (48.7 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Catherine Van Poznak is an Oncologist and a Hematologist in Ann Arbor, Michigan. Dr. Van Poznak is rated as an Advanced provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Angiosarcoma, Inflammatory Breast Cancer, Paget Disease of the Breast, and Breast Cancer. Dr. Van Poznak is currently accepting new patients.

Distinguished in Inflammatory Breast Cancer
Dr. Jeffrey B. Smerage
Oncology | Hematology | Public Health and Preventive Medicine
Distinguished in Inflammatory Breast Cancer
Dr. Jeffrey B. Smerage
Oncology | Hematology | Public Health and Preventive Medicine

Regents Of The University Of Michigan

1500 E Medical Ctr, Suite 0331, 
Ann Arbor, MI 
 (48.6 miles away)
734-936-5738
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Smerage is an Oncologist and a Hematologist in Ann Arbor, Michigan. Dr. Smerage is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Breast Cancer, Angiosarcoma, Inflammatory Breast Cancer, and Paget Disease of the Breast. Dr. Smerage is currently accepting new patients.

Distinguished in Inflammatory Breast Cancer
Dr. Aki Morikawa
Oncology | Hematology | Hematology Oncology
Distinguished in Inflammatory Breast Cancer
Dr. Aki Morikawa
Oncology | Hematology | Hematology Oncology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr, 
Ann Arbor, MI 
 (48.7 miles away)
Languages Spoken:
English, Japanese
See accepted insurances
Accepting New Patients
Offers Telehealth

Aki Morikawa is an Oncologist and a Hematologist in Ann Arbor, Michigan. Dr. Morikawa is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Angiosarcoma. Dr. Morikawa is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hrinczenko's expertise for a condition
ConditionClose
      View All 48 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile